S412
Clinical - Gynaecological
ESTRO 2026
Digital Poster Highlight 784
carcinoma. At first relapse, 45 % (n=39) of relapses were distal and 33 % of relapses (n=28) were a combination of distant and loco-regional metastasis. 9 % (n=8) were isolated para-aortic relapses and 9 % (n=8) were isolated vaginal relapses. Isolated pelvic recurrences occurred in 4 % (n=3) and were the least common.Routine surveillance cross sectional imaging with CT was the most effective method of detecting recurrence, identifying 63 % (n=54) of relapses in asymptomatic patients, especially nodal and distal recurrences. In 35% of the relapses (n=30), patients presented with symptoms which led to confirmation of relapse by examination and/or imaging. Clinical examination identified isolated local relapses in 0.9 % (n=2) patients who were asymptomatic and relapse was subsequently confirmed on further imaging.
Refining surveillance strategies: Modes of detection and patterns of relapse after adjuvant EBRT in endometrial cancer Ayesha Sathali, Jeyaanth Venkatasai, Ingrid White, Benjamin Taylor, Anna Winship, Priyanka Patel Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom Purpose/Objective: To rationalise follow-up pathways after adjuvant External beam radiotherapy (EBRT) in endometrial cancers by identifying modes of detection of relapse Material/Methods: Retrospective analysis of all patients treated at our centre with adjuvant pelvic EBRT for International Federation of Gynaecology and Obstetrics (FIGO) stage I-IV endometrial cancer of all histological subtypes from January 2018 to May 2023. Patient and tumour characteristics, treatment details, relapse, death and last follow up dates were collected. Sites of relapse, presence of symptoms, modes of detection and confirmation of relapse were determined. European Society of Medical Oncology- European Society of Gynaecological Oncology (ESMO-ESTRO) 2020 risk stratification was assigned, and relapse free and overall survival were estimated[1]. All our patients had surveillance follow up for five years from completion of treatment with clinical examination, including pelvic exam and annual CT scan. Results: Data from 228 patients were analysed. Median age was 65 years (range 37-85) and median follow up duration was 47 months (interquartile range 36-70). In total 37.7 % (n=86) of patients relapsed, 2.2 % (n=5) from the intermediate risk group, 4.4 % (n=10) from the high-intermediate risk group and 23.7 % (n=54) from the high-risk group and 7.4 % (n=17) in the advanced/ metastatic group. 39.5% of relapses (n=34) had serous
Conclusion: Recurrences occurred in 37.7 % of our patients and of these 97.7 % were detected following symptoms or routine CT imaging. Our data supports use of patient-initiated follow-up (PIFU) after EBRT in endometrial cancer, keeping with the British Gynaecological Cancer Society guidance on PIFU[2]. It also supports regular CT imaging
Made with FlippingBook - Share PDF online